Axsome COO sells 10,000 shares after option exercise
Axsome Therapeutics’ chief operating officer exercised long-held options and sold 10,000 shares under a pre-approved Rule 10b5-1 trading plan.
Rhea-AI Filing Summary
Axsome Therapeutics, Inc. (AXSM) reported that Chief Operating Officer Mark L. Jacobson exercised stock options for 10,000 shares of common stock on September 3, 2026 at an exercise price of $12.95 per share, then sold 10,000 shares of common stock the same day at a weighted average price of $208.65 per share. The options exercised had been held for about seven years and were exercised before their March 19, 2029 expiration. Jacobson continues to hold 104,954 stock options after the transaction, and the transactions were carried out under a pre-approved Rule 10b5-1 trading plan, with sale prices ranging between $206.41 and $210.34.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($1.96M approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
Jacobson Mark L.
Role
Chief Operating Officer
Sold
10,000 shs ($2.09M)
Approx. gross sale proceeds
$2.09M
Approx. exercise cost
$130K
Approx. pre-tax spread
$1.96M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) F1, F2 | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1, F2 | 10,000 | $12.95 | $130K |
| Sale | Common Stock F2, F3, F4 | 10,000 | $208.65 | $2.09M |
Holdings After Transaction:
Stock Option (Right to Buy) — 104,954 contracts (Direct);
Common Stock — 0 shares (Direct)
Footnotes (4)
- F1. Represents an exercise of stock options which were held for 7 years and exercised prior to the 10 year expiration date of such options.
- F2. Such transaction was pursuant to a pre-approved 10b5-1 plan.
- F3. Represents the subsequent sale of the underlying shares of the aforementioned exercise of stock options.
- F4. Represents the weighted average sale price of a series of open market transactions with sale prices ranging between $206.41 and $210.34.
Key Figures
Options exercised: 10,000 shares
Exercise price: $12.95 per share
Shares sold: 10,000 shares
+4 more
7 metrics
Options exercised
10,000 shares
Stock options for Axsome Therapeutics common stock exercised on September 3, 2026
Exercise price
$12.95 per share
Exercise price of stock options exercised on September 3, 2026
Shares sold
10,000 shares
Common shares sold on September 3, 2026 following option exercise
Weighted average sale price
$208.65 per share
Weighted average price of open market sales on September 3, 2026
Sale price range
$206.41–$210.34 per share
Range of prices for the series of open market sales on September 3, 2026
Options held after transaction
104,954 options
Stock options for Axsome Therapeutics common stock held after the reported exercise
Option expiration date
March 19, 2029
Expiration date of the stock options that were exercised for 10,000 shares
Key Terms
Rule 10b5-1 plan, stock options, weighted average sale price
3 terms
Rule 10b5-1 plan regulatory
"Such transaction was pursuant to a pre-approved 10b5-1 plan."
A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.
stock options financial
"Represents an exercise of stock options which were held for 7 years"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
weighted average sale price financial
"Represents the weighted average sale price of a series of open market transactions"
FAQ
What insider transactions did AXSM’s chief operating officer report on September 3, 2026?
Mark L. Jacobson reported exercising 10,000 stock options at $12.95 per share and selling 10,000 shares of Axsome Therapeutics common stock the same day at a weighted average price of $208.65 per share, in open market transactions.
Were the September 3, 2026 AXSM insider transactions under a Rule 10b5-1 plan?
Yes. The filing states that the transactions were carried out pursuant to a pre-approved Rule 10b5-1 plan, indicating they followed a pre-established trading schedule rather than being initiated at the time of the trades.
What stock options did the AXSM COO exercise in this Form 4 filing?
Mark L. Jacobson exercised 10,000 stock options for Axsome Therapeutics common stock at an exercise price of $12.95 per share. The options had been held for about seven years and were exercised before their March 19, 2029 expiration date.
How many Axsome Therapeutics options does the COO hold after these transactions?
After exercising and selling shares related to this grant, Mark L. Jacobson continues to hold 104,954 stock options of Axsome Therapeutics, according to the reported post-transaction derivative holdings in the filing.
Did the AXSM COO acquire or sell any other securities in this Form 4?
The Form 4 reports a single options exercise for 10,000 shares of common stock and a related sale of 10,000 shares of common stock. No additional acquisitions or dispositions are disclosed in this filing.
AI-generated analysis. How Rhea-AI works. Not financial advice.
